Catalog No.
Product Name
Application
Product Information
Citations
-
c-Myc Inhibitor
10074-G5 is a c-Myc inhibitor by inhibiting c-Myc/Max heterodimer formation and inhibiting its transcriptional activity with IC50 value of 146 μM. 10074-G5 binds to and distorts the bHLH-ZIP domain of c-Myc, thereby inhibiting c-Myc/Max heterodimer formation and inhibiting its transcriptional activity. 10074-G5 is capable of binding and sequestering the intrinsically disordered amyloid-β (Aβ) peptide in its monomeric, soluble state. Our analysis reveals that this compound interacts with Aβ and inhibits both the primary and secondary nucleation pathways in its aggregation process.
- c-Myc Peptide (TFA) is a synthetic peptide corresponding to the C-terminal amino acids (410-419) of human c-myc protein, and participates in regulation of growth-related gene transcription.
-
Staurosporine Analog
Stauprimide is a staurosporine analog that promotes embryonic stem cell (ESC) differentiation. It selectively binds to the MYC transcriptional regulator NME2, blocking its nuclear localization in ESCs and thereby downregulating MYC transcription. -
MYC-MAX degrader
MDEG-541 is a potent PROTAC degrader targeting the MYC-MAX complex, derived from the MYC-MAX dimerization inhibitor 10058-F4 (28RH) and thalidomide as the cereblon-recruiting ligand. It exhibits strong antiproliferative activity and reduces the expression of key oncogenic and regulatory proteins, including GSPT1, MYC, GSPT2, and PLK1. MDEG-541 is a valuable tool for studying MYC-driven cancers and targeted protein degradation strategies. -
MYC RIBOTAC
MYC-RIBOTAC is a ribonuclease-targeting chimera (RIBOTAC) designed to degrade MYC mRNA by targeting its internal ribosome entry site (IRES). It combines a MYC mRNA-binding moiety with a small molecule that recruits and activates RNase L1. MYC-RIBOTAC reduces MYC mRNA and protein levels, induces apoptosis, and holds promise for antitumor research. -
c-MYC Inhibitor
IZTZ-1 is an imidazole-benzothiazole conjugate that functions as a c-MYC inhibitor by stabilizing the G-quadruplex (G4) structure of c-MYC. This stabilization results in the downregulation of c-MYC expression, leading to induction of cell cycle arrest and apoptosis in various cell lines, including B16 melanoma cells. Due to its ability to inhibit cell proliferation and exhibit antitumor activity, IZTZ-1 is a valuable tool for researchers studying melanoma and related cancer pathways. -
c-Myc Inhibitor
CMLD010509 is a selective inhibitor of c-Myc, targeting the oncogenic translation program associated with multiple myeloma (MM). This compound demonstrates an IC50 of less than 10 nM in various MM cell lines and effectively induces apoptosis. CMLD010509 operates through a phosphorylation-independent mechanism, making it a valuable tool for studying the role of translation in oncogenesis and developing targeted therapeutic strategies in MM research. -
c-Myc Inhibitor
Y502-3888 is a selective c-Myc inhibitor that targets the G-quadruplex (G4) structure of c-Myc, effectively impairing its transcriptional activity. This compound downregulates c-Myc expression at both mRNA and protein levels, leading to reduced viability and induced apoptosis in myeloma cells. Y502-3888 serves as a valuable tool for investigating the role of c-Myc in multiple myeloma and other related malignancies. -
c-Myc G4 Stabilizer
GQC-05 is a selective c-Myc G-quadruplex (c-Myc G4) stabilizer that demonstrates potent activity with KD values ranging from 0.1 to 1.43 μM. This compound effectively reduces c-Myc expression, leading to the induction of apoptosis in cancer cells. GQC-05 serves as a valuable tool in cancer research, particularly in studying conditions such as Burkitt lymphoma. -
c-Myc G4 Inhibitor
c-Myc inhibitor 16 iodide is a selective inhibitor of the c-Myc G-quadruplex, effectively targeting the c-Myc gene's transcription and translation processes. It disrupts the tumor cell cycle by arresting growth in the G0/G1 phase and activates the mitochondrial apoptosis pathway, leading to early apoptosis in cancer cells. This compound has significant potential in research applications related to breast cancer. -
c-Myc Inhibitor
EP12 is a selective c-Myc inhibitor that stabilizes c-Myc G-quadruplexes. This compound induces apoptosis and causes DNA damage in multiple myeloma cells, effectively inhibiting their growth. Additionally, EP12 disrupts the nuclear translocation of P65/P50 by interfering with the NF-κB signaling pathway, highlighting its potential in cancer research and therapeutic applications. -
c-Myc Inhibitor
(-)-CMLD010509 is a potent c-Myc inhibitor that selectively targets the oncogenic translation program associated with multiple myeloma. This compound demonstrates significant activity, exhibiting an IC50 of less than 10 nM in various multiple myeloma cell lines, leading to the induction of apoptosis. (-)-CMLD010509 operates through a mechanism that is independent of eIF4E phosphorylation, making it a valuable tool for studying the translation control of key oncoproteins such as MYC, MDM2, CCND1, MAF, and MCL-1. -
c-Myc G-quadruplex Stabilizer
Y502-2304 is a potent c-Myc G-quadruplex stabilizer that exhibits significant antiproliferative activity in multiple myeloma (MM) cells. It effectively downregulates both c-Myc mRNA and protein expression, leading to the induction of apoptosis characterized by increased γH2AX levels and elevated reactive oxygen species (ROS). Additionally, Y502-2304 disrupts mitochondrial function and demonstrates a marked inhibition of tumor growth in xenograft models of MM. This compound is suitable for various research applications focused on elucidating the molecular mechanisms underlying multiple myeloma. -
FLuc Inhibitor
GW694590A is an inhibitor targeting firefly luciferase (Fluc) that enhances the stability of the MYC protein, subsequently increasing its endogenous levels. This compound also inhibits receptor tyrosine kinases, demonstrating significant reductions in DDR2, KIT, and PDGFRα activity at 1 μM. GW694590A serves as a versatile protein kinase inhibitor, influencing both ATP-dependent and -independent luciferase systems, making it valuable for studies in cellular signaling and gene expression regulation. -
c-Myc Inhibitor
KSI-3716 is a potent c-Myc inhibitor that disrupts the binding of c-Myc to MAX, preventing the transcription of target genes. This compound serves as an effective agent in intravesical chemotherapy for bladder cancer, demonstrating significant antitumor activity. Its ability to modulate c-Myc signaling makes it a valuable tool for research into cancer biology and potential therapeutic interventions. -
c-Myc Inducer
DMBA (7,12-Dimethylbenz(a)anthracene) is a potent c-Myc inducer known for its role as a carcinogen due to its polycyclic aromatic hydrocarbon structure. This compound is widely utilized in experimental research to induce tumor formation in rodent models, enabling the study of cancer biology, tumorigenesis, and potential therapeutic interventions. Its application is critical in understanding the mechanisms of cancer development and the role of oncogenes. -
c-Myc Inhibitor
WBC100 is a selective c-Myc inhibitor that functions as a molecular glue degrader targeting the ubiquitin E3 ligase CHIP to promote degradation via the 26S proteasome pathway. This compound demonstrates potent activity in models of c-Myc overexpressing tumors, enabling researchers to study its effects on tumor growth and progression. WBC100 is a valuable tool for investigating the role of c-Myc in various cancer types and for exploring potential therapeutic strategies. -
c-MYC Inhibitor
MY05 is a selective inhibitor of the c-MYC protein, effectively disrupting the MYC-MAX interaction. This compound engages intracellular c-MYC, modulating its thermal stability and leading to a reduction in c-MYC transcriptional targets. MY05 demonstrates significant anticancer activity, particularly in triple-negative breast cancer (TNBC), making it a valuable tool for research in cancer biology and therapeutics. -
c-Myc Inhibitor
c-Myc inhibitor 6 is a selective c-Myc inhibitor that effectively reduces cancer cell viability while promoting the degradation of the c-Myc protein. This compound is invaluable for research into c-Myc dysregulation, which is implicated in various pathologies, including cancer, cardiovascular diseases, and viral infections. Its ability to target c-Myc positions it as a potential therapeutic agent in studies aimed at understanding and treating these conditions. -
c-Myc Inhibitor
c-Myc ligand 1 is a potent c-Myc inhibitor that functions as a target protein ligand for PROTAC (Proteolysis Targeting Chimera) technology. This compound is essential for the synthesis of the PROTAC c-Myc inhibitor 7, facilitating studies in cellular regulation and tumorigenesis. It serves as a critical tool in research focused on targeting and degrading oncogenic proteins associated with various cancers. -
c-MYC IRES inhibitor
IRES-C11 is an inhibitor of the c-MYC internal ribosome entry site (IRES) that specifically disrupts the interaction between the c-MYC IRES and its essential trans-acting factor, heterogeneous nuclear ribonucleoprotein A1. This selective inhibition allows for targeted modulation of c-MYC translation without affecting other IRES-mediated translations, such as those involving BAG-1, XIAP, and p53. IRES-C11 is a valuable tool for research investigating the regulatory mechanisms of c-MYC translation and its implications in cancer biology. -
c-Myc Inhibitor
10074-A4 is a potent inhibitor of the c-Myc oncogenic transcription factor. It binds to the c-Myc peptide at various sites along its sequence, interfering with its function and modulating gene expression. This compound exhibits significant anticancer activity, making it a valuable tool for research into c-Myc-related pathways and cancer therapeutics. -
c-Myc Inhibitor
Lusianthridin is a c-Myc inhibitor derived from Dendrobium venustum. This compound has demonstrated significant anti-migratory effects by enhancing c-Myc degradation, primarily through the inhibition of the Src-STAT3 signaling pathway. Lusianthridin is valuable for research applications focused on cancer biology and the regulation of gene expression associated with cell migration and proliferation. -
c-Myc Inhibitor
m-Se3 is a potent and selective inhibitor of the c-Myc transcription factor. By disrupting c-Myc activity, m-Se3 effectively inhibits tumor growth and demonstrates significant anti-cancer activity across various cancer models. This compound is useful for research related to cancer biology and therapeutic strategies targeting c-Myc-driven malignancies. -
c-Myc Inhibitor
APTO-253 hydrochloride is a small molecule c-Myc inhibitor that stabilizes G-quadruplex DNA, leading to cell cycle arrest and apoptosis in acute myeloid leukemia cells. This compound exerts its anticancer effects through the induction of the tumor suppressor Kruppel-like factor 4 (KLF4). Additionally, APTO-253 hydrochloride has demonstrated antiarthritic activity, contributing to its potential application in various cancer and inflammatory disease research studies. -
c-Myc Inhibitor
c-Myc inhibitor 14 (Compound 13A) is a selective inhibitor of the c-Myc protein, demonstrating an IC50 value of less than 100 nM in HL60 cell lines. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. Its ability to target c-Myc positions it as a promising candidate for studies focused on tumorigenesis and therapeutic interventions in c-Myc-driven malignancies. -
c-Myc Inhibitor
c-Myc inhibitor 10 is a selective inhibitor targeting the c-Myc protein. This compound demonstrates enhanced cellular potency, attributed to improved permeability achieved through the methylation of the morpholine nitrogen. It is useful for research applications investigating the role of c-Myc in oncogenesis and related signaling pathways. -
c-Myc Inhibitor
c-Myc inhibitor 8 is a potent inhibitor of the c-Myc transcription factor, a key regulator of cell proliferation and growth in various cancers. This compound effectively reduces cell viability in a range of cancer cell lines and shows significant inhibition of human prostate and lung cancer growth in mouse models. c-Myc inhibitor 8 is suitable for applications in cancer research, particularly in studies exploring therapeutic strategies targeting c-Myc-driven tumors. -
c-Myc Inhibitor
c-Myc inhibitor 12 is a selective inhibitor targeting the transcription factor c-Myc, exhibiting a pEC50 of 6.4. This compound demonstrates significant anti-cancer activity by disrupting c-Myc-mediated transcriptional regulation. It serves as a valuable research tool for investigating the role of c-Myc in cellular proliferation and tumorigenesis, enabling studies on potential therapeutic strategies in oncology. -
c-Myc Inhibitor
c-Myc inhibitor 9 is a selective inhibitor of c-Myc, exhibiting an logEC50 of ≥6. This compound has demonstrated the ability to inhibit tumor growth in nude mouse models, making it a valuable tool in cancer research. c-Myc inhibitor 9 provides researchers with a means to explore the role of c-Myc in tumor proliferation and therapeutic strategies targeting this oncogenic transcription factor. -
c-Myc Inhibitor
c-Myc inhibitor 4 is a potent inhibitor targeting the c-Myc oncogene. This compound effectively reduces c-Myc levels, making it a valuable tool in cancer research, particularly for studies focused on tumors driven by c-Myc overexpression. Its oral bioavailability facilitates in vivo research, allowing for the exploration of therapeutic implications in various malignancies. -
c-MYC Inhibitor
NUCC-0201642 is a selective c-MYC inhibitor, demonstrating an IC50 value greater than 40 μM. This compound is utilized in cancer research to explore the role of c-MYC in tumorigenesis and to investigate potential therapeutic strategies targeting c-MYC-driven malignancies. Its application may aid in the development of novel treatments for cancers characterized by elevated c-MYC expression.
